Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer.
Expression of the c-erbB-2 oncogene protein was investigated by immunohistochemistry in 110 paraffin-embedded blocks of primary breast cancer. 25 (22.7%) of 110 tumors were stained positively with c-erbB-2 protein antibody. There was no correlation between c-erbB-2 immunostaining and age at diagnosis, menopausal status, hormone receptor status, tumor size, or clinical stage. The tumors with an extensive intraductal component showed a higher incidence of the c-erbB-2 expression than those without. A significantly shorter overall survival was obtained in patients with the expression of c-erbB-2 protein than in patients without. Staining of c-erbB-2 protein is an effective prognostic indicator in patients with breast cancer.
Horiguchi
J
J
Department of Surgery, Gunma University School of Medicine, Maebashi, Japan.
Iino
Y
Y
Takei
H
H
Yokoe
T
T
Ishida
T
T
Morishita
Y
Y
D000367:Age Factors; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D002277:Carcinoma / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D066246:ErbB Receptors / Q000032:analysis* / Q000096:biosynthesis*; D005260:Female; D005500:Follow-Up Studies; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D017698:Postmenopause; D017697:Premenopause; D011518:Proto-Oncogene Proteins / Q000032:analysis* / Q000096:biosynthesis*; D011519:Proto-Oncogenes; D018719:Erb-b2 Receptor Tyrosine Kinases; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors
D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases